Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma heart disease.

B Marasini1, M Massarotti, R Cossutta

  • 1Rheumatology Unit, Humanitas Clinical Institute, University of Milan, Italy. bianca.marasini@humantias.it

International Journal of Immunopathology and Pharmacology
|January 4, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outbreak Investigation of Influenza in Pajaru VDC of Jajarkot District of Nepal.

Journal of Nepal Health Research Council·2017
Same author

Effects of type II collagen epitope carbamylation and citrullination in human leucocyte antigen (HLA)-DR4(+) monozygotic twins discordant for rheumatoid arthritis.

Clinical and experimental immunology·2016
Same author

Osteoanabolic therapy: a valid option to reduce refracture risk after vertebral augmentation procedures?

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2016
Same author

Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.

Lupus·2015
Same author

Statins and cardiovascular risk in rheumatic diseases.

International journal of immunopathology and pharmacology·2012
Same author

Shock wave therapy for systemic sclerosis.

Rheumatology international·2011
Same journal

Glycolysis and neutrophil extracellular traps in atherosclerosis: Mechanisms, association, and therapeutic strategies.

International journal of immunopathology and pharmacology·2026
Same journal

Development of RNase P ribozyme-based therapy against oral herpesvirus infections by HSV-1 and KSHV.

International journal of immunopathology and pharmacology·2026
Same journal

Liposomal nanotherapeutics for cancer treatment: Targeted delivery and immunotherapy.

International journal of immunopathology and pharmacology·2026
Same journal

Apoptosis enhancement in MCF-7 cells: Synergistic effects of doxorubicin and the novel sulfonamide Zm-093.

International journal of immunopathology and pharmacology·2026
Same journal

Primary epithelioid angiosarcoma of thyroid: A case report and review of literature.

International journal of immunopathology and pharmacology·2026
Same journal

Retraction: Adipose stem cells' antagonism in glycosylation of D-galactose-induced skin aging of nude mice and its skin recovery function.

International journal of immunopathology and pharmacology·2026
See all related articles

Systemic sclerosis can cause severe heart disease, particularly cardiomyopathy with diastolic dysfunction and arrhythmias, leading to a poor prognosis. Early detection via coronary microcirculation dysfunction is key for managing this often asymptomatic condition.

Area of Science:

  • Cardiology
  • Rheumatology
  • Internal Medicine

Background:

  • Heart disease is a common and severe complication of systemic sclerosis (scleroderma).
  • Cardiomyopathy, characterized by ventricular diastolic dysfunction and arrhythmias, significantly worsens prognosis in scleroderma patients.
  • Identifying at-risk individuals and defining the pattern of cardiac involvement remains challenging due to difficulties in in vivo evaluation.

Purpose of the Study:

  • To provide an updated review of the clinical aspects of scleroderma heart disease.
  • To highlight the critical role of coronary microcirculation dysfunction in the early development of cardiac complications.
  • To discuss available diagnostic tools for this often asymptomatic condition and review current treatment strategies.

Main Methods:

Related Experiment Videos

  • Literature review focusing on clinical aspects, pathophysiology, diagnostics, and therapeutics of scleroderma heart disease.
  • Analysis of studies examining coronary microcirculation dysfunction in systemic sclerosis.
  • Evaluation of diagnostic modalities and treatment options for cardiac involvement in scleroderma.

Main Results:

  • Coronary microcirculation dysfunction is an early and pivotal factor in the development of scleroderma heart disease.
  • Diagnostic tools are available to assess cardiac involvement, even in asymptomatic patients.
  • Current treatment for scleroderma-related diastolic dysfunction is unsatisfactory, and no cure for systemic sclerosis exists.

Conclusions:

  • Scleroderma heart disease, especially cardiomyopathy, poses a significant threat with a poor prognosis.
  • Early identification of coronary microcirculation dysfunction is crucial for risk stratification and management.
  • Further research is needed to improve diagnostic accuracy and develop effective therapies for this condition.